Image

A Phase 1/2 Study of Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Investigating the Effects of an Investigational Medication with or without an Additional Agent in Treating Solid Tumors That Have Returned or Are Resistant to Treatment in Younger Patients

Recruiting
1-30 years
All
Phase N/A
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates the effects of an investigational medication, given with or without an additional agent, on younger patients with solid tumors or sarcomas that have either returned after treatment or do not respond to treatment. Solid tumors are masses of tissue that can occur in various parts of the body, and sarcomas are a type of cancer that arises from connective tissues such as bone or muscle. The study aims to find the best dose and understand the side effects of the treatment.

Participants in this study will receive either the investigational medication alone or in combination with an additional agent. The study will monitor for side effects and determine the most effective dose. Participants will undergo various medical assessments to evaluate the treatment's impact on their condition.

  • Who can participate: Patients aged 18 and under must have a confirmed diagnosis of solid tumors or sarcomas that are recurrent or refractory. They should have recovered from previous cancer treatments and must not have previously received the investigational medication. Pregnant or breastfeeding women, and those with certain medical conditions, are not eligible.
  • Study details: Participants will receive the investigational medication, either alone or with an additional agent. A placebo, which is an inactive substance, will not be used in this study. The study will involve monitoring the patients for any side effects and assessing the optimal dosage.
Print
Study details
    Cancer
    Solid Tumor

TX5069

19 February 2024

Contact a study center
Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Please provide your preferred way of contact1234
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.